marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Sarepta Therapeutics Balance Sheet 2011-2024 | SRPT
Annual Balance Sheet Sarepta Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
827 M | 593 M | -1.55 B | -510 M | 136 M | 853 M | -169 M | -106 M | -56.9 M | -67.2 M | -255 M | -186 M | -38.1 M |
Long Term Debt |
1.24 B | 1.54 B | 564 M | 992 M | 682 M | 421 M | 425 M | 6.04 M | 15 M | 3.74 M | 1.58 M | 1.67 M | 1.76 M |
Long Term Debt Current |
17.8 M | 15.5 M | - | - | - | - | - | - | - | 98 K | 92 K | 89 K | 85 K |
Total Non Current Liabilities |
- | - | - | - | 740 M | 436 M | 430 M | 12 M | 21.1 M | 10.5 M | 8.41 M | 2.43 M | 2.75 M |
Total Current Liabilities |
654 M | 620 M | 453 M | 416 M | 265 M | 174 M | 88.3 M | 75.4 M | 62.3 M | 36.9 M | 36 M | 78.9 M | 20.6 M |
Total Liabilities |
2.41 B | 2.74 B | 2.22 B | 2.22 B | 1 B | 610 M | 519 M | 87.4 M | 83.4 M | 47.4 M | 44.4 M | 81.3 M | 23.4 M |
Deferred Revenue |
50.4 M | 89.2 M | 89.2 M | 89.2 M | - | 3.3 M | 3.32 M | 3.3 M | 3.3 M | 3.32 M | 3.3 M | 3.3 M | 3.3 M |
Retained Earnings |
-4.45 B | -3.91 B | -3.21 B | -2.85 B | -2.29 B | -1.58 B | -1.22 B | -1.17 B | -899 M | -679 M | -543 M | -431 M | -310 M |
Total Assets |
3.26 B | 3.13 B | 3.15 B | 2.98 B | 1.82 B | 1.64 B | 1.31 B | 424 M | 274 M | 295 M | 292 M | 205 M | 54.4 M |
Cash and Cash Equivalents |
428 M | 967 M | 2.12 B | 1.5 B | 835 M | 371 M | 600 M | 122 M | 80.3 M | 73.6 M | 257 M | 188 M | 39.9 M |
Book Value |
859 M | 385 M | 928 M | 762 M | 818 M | 1.03 B | 789 M | 337 M | 190 M | 248 M | 247 M | 124 M | 31 M |
Total Shareholders Equity |
859 M | 385 M | 928 M | 762 M | 818 M | 1.03 B | 789 M | 337 M | 190 M | 248 M | 247 M | 124 M | 31 M |
All numbers in USD currency
Quarterly Balance Sheet Sarepta Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.23 B | 1.23 B | 1.24 B | 1.24 B | 1.24 B | 1.24 B | 1.23 B | 1.54 B | 1.54 B | - | 38.6 M | 564 M | 63.4 M | 65.3 M | 60.7 M | 80.4 M | 80.4 M | 80.4 M | 80.4 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 421 M | 415 M | 439 M | 431 M | 431 M | 431 M | 431 M | 431 M | 17.7 M | - | - | - | 26.8 M | - | - | 1.45 M | 1.48 M | 1.5 M | 1.52 M | 1.55 M | 1.58 M | 1.58 M | 1.58 M | 1.58 M | 1.67 M | 1.67 M | 1.67 M | 1.67 M | 1.76 M | 1.76 M | 1.76 M | 1.76 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.8 M | 757 K | 755 K | 760 K | 758 K | 760 K | 760 K | 993 K | 993 K | 993 K | 993 K |
Total Liabilities |
2.38 B | 2.35 B | 2.26 B | 2.41 B | 2.35 B | 2.38 B | 2.35 B | 2.74 B | 2.73 B | - | 2.2 B | 2.22 B | 2.19 B | 2.27 B | 2.23 B | 2.22 B | 2.22 B | 2.22 B | 2.22 B | 1 B | 1 B | 1 B | 1 B | 610 M | 610 M | 610 M | 610 M | 519 M | 519 M | 519 M | 519 M | 87.4 M | 87.4 M | 87.4 M | 87.4 M | 83.4 M | 83.4 M | 83.4 M | 83.4 M | 47.4 M | 47.4 M | 47.4 M | 47.4 M | 44.4 M | 44.4 M | 44.4 M | 44.4 M | 81.3 M | 81.3 M | 81.3 M | 81.3 M | - | - | - | - |
Deferred Revenue |
127 M | 122 M | 112 M | 50.4 M | 22.5 M | 45 M | 67.2 M | 89.2 M | 89.2 M | - | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.32 M | 3.3 M | 3.32 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.32 M | 3.32 M | 3.32 M | 3.32 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M |
Retained Earnings |
-4.37 B | -4.4 B | -4.41 B | -4.45 B | -4.49 B | -4.45 B | -4.43 B | -3.91 B | -3.8 B | - | -3.31 B | -3.21 B | -3.08 B | -3.04 B | -2.96 B | -2.85 B | -2.85 B | -2.85 B | -2.85 B | -2.29 B | -2.29 B | -2.29 B | -2.29 B | -1.58 B | -1.58 B | -1.58 B | -1.58 B | -1.22 B | -1.22 B | -1.22 B | -1.22 B | -1.17 B | -1.17 B | -1.17 B | -1.17 B | -899 M | -899 M | -899 M | -899 M | -679 M | -679 M | -679 M | -679 M | -543 M | -543 M | -543 M | - | - | - | - | - | - | - | - | - |
Total Assets |
3.6 B | 3.42 B | 3.22 B | 3.26 B | 3.11 B | 3.13 B | 3.06 B | 3.13 B | 3.16 B | - | 3.06 B | 3.15 B | 2.66 B | 2.76 B | 2.77 B | 2.98 B | 2.98 B | 2.98 B | 2.98 B | 1.82 B | 1.82 B | 1.82 B | 1.82 B | 1.64 B | 1.64 B | 1.64 B | 1.64 B | 1.31 B | 1.31 B | 1.31 B | 1.31 B | 424 M | 424 M | 424 M | 424 M | 274 M | 274 M | 274 M | 274 M | 295 M | 295 M | 295 M | 295 M | 292 M | 292 M | 292 M | 292 M | 205 M | 205 M | 205 M | 205 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M |
Cash and Cash Equivalents |
198 M | 384 M | 427 M | 428 M | 542 M | 852 M | 872 M | 967 M | 1.04 B | 869 M | 1.23 B | 2.12 B | 1.6 B | 1.7 B | 1.48 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 835 M | 835 M | 835 M | 835 M | 371 M | 371 M | 371 M | 371 M | 600 M | 600 M | 600 M | 600 M | 122 M | 122 M | 122 M | 122 M | 80.3 M | 80.3 M | 80.3 M | 80.3 M | 73.6 M | 73.6 M | 73.6 M | 73.6 M | 257 M | 257 M | 257 M | 257 M | 188 M | 188 M | 188 M | 188 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M |
Book Value |
1.22 B | 1.08 B | 961 M | 859 M | 764 M | 741 M | 713 M | 385 M | 431 M | - | 857 M | 928 M | 470 M | 485 M | 535 M | 762 M | 762 M | 762 M | 762 M | 818 M | 818 M | 818 M | 818 M | 1.03 B | 1.03 B | 1.03 B | 1.03 B | 789 M | 789 M | 789 M | 789 M | 337 M | 337 M | 337 M | 337 M | 190 M | 190 M | 190 M | 190 M | 248 M | 248 M | 248 M | 248 M | 247 M | 247 M | 247 M | 247 M | 124 M | 124 M | 124 M | 124 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M |
Total Shareholders Equity |
1.22 B | 1.08 B | 961 M | 859 M | 764 M | 741 M | 713 M | 385 M | 431 M | 726 M | 857 M | 928 M | 470 M | 485 M | 535 M | 762 M | 762 M | 762 M | 762 M | 818 M | 818 M | 818 M | 818 M | 1.03 B | 1.03 B | 1.03 B | 1.03 B | 789 M | 789 M | 789 M | 789 M | 337 M | 337 M | 337 M | 337 M | 190 M | 190 M | 190 M | 190 M | 248 M | 248 M | 248 M | 248 M | 247 M | 247 M | 247 M | 247 M | 124 M | 124 M | 124 M | 124 M | 31 M | 31 M | 31 M | 31 M |
All numbers in USD currency